|
2023 Conference Publication Reducing hospital resource utilization and improving patient satisfaction with an innovative inflammatory bowel disease nurse-led clinical care pathway with rapid-access intestinal ultrasoundFernandes, R., Harris, H., Khoo, E., Gilmore, R., Howlett, M., Walker, N., Hendy, P., Begun, J. and An, Y-K (2023). Reducing hospital resource utilization and improving patient satisfaction with an innovative inflammatory bowel disease nurse-led clinical care pathway with rapid-access intestinal ultrasound. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Vedolizumab has longer persistence than infliximab for ulcerative colitis in a real-world cohort study: Preliminary results from the COMPARE-IT studyAnandan, A. Shanmuga, Fernandes, R., Etchegaray, A., Malloy, R., Selvanathan, P., Gilmore, R., Pham, H., Begun, J. and An, Y-K (2023). Vedolizumab has longer persistence than infliximab for ulcerative colitis in a real-world cohort study: Preliminary results from the COMPARE-IT study. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Australian consensus on ustekinumab in Crohn's diseaseBegun, J., An, Y-K, Bryant, R., Christensen, B., Leong, R., Studd, C. and Thin, L. (2023). Australian consensus on ustekinumab in Crohn's disease. HOBOKEN: WILEY. |
|
2023 Conference Publication Withdrawal vs continuation of thiopurine in vedolizumab-treated patients with ulcerative colitis (VIEWS): A multicenter randomized controlled trialPudipeddi, A., Paramsothy, S., Kariyawasam, V., Paramsothy, R., Ghaly, S., Haifer, C., An, Y-K, Begun, J., Connor, S., Corte, C., Ward, M., De Cruz, P., Fung, C., Redmond, D., Chan, W., Mourad, F. and Leong, R. (2023). Withdrawal vs continuation of thiopurine in vedolizumab-treated patients with ulcerative colitis (VIEWS): A multicenter randomized controlled trial. HOBOKEN: WILEY. |
|
2023 Conference Publication Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experienceGilmore, R., Fernandes, R., Schildkraut, T., Joshi, R., Lin, L., Etchegaray, A., Anandan, A. Shanmuga, Begun, J., An, Y-K and Wright, E. (2023). Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experience. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Journal Article MUC13 cell surface mucin limits Salmonella Typhimurium infection by protecting the mucosal epithelial barrierMcGuckin, Michael A., Davies, Julie M., Felgner, Pascal, Wong, Kuan Yau, Giri, Rabina, He, Yaowu, Moniruzzaman, Md., Kryza, Thomas, Sajiir, Haressh, Hooper, John D., Florin, Timothy H., Begun, Jakob, Oussalah, Abderrahim, Hasnain, Sumaira Z., Hensel, Michael and Sheng, Yong H. (2023). MUC13 cell surface mucin limits Salmonella Typhimurium infection by protecting the mucosal epithelial barrier. Cellular and Molecular Gastroenterology and Hepatology, 16 (6), 985-1009. doi: 10.1016/j.jcmgh.2023.08.011 |
|
2023 Conference Publication Upadacitinib for rescue therapy in patients with acute severe ulcerative colitis: An Australian real-world experienceTan, W. L., Gilmore, R., Huang, A., Fernandes, R., An, Y-K and Begun, J. (2023). Upadacitinib for rescue therapy in patients with acute severe ulcerative colitis: An Australian real-world experience. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Variation of outcomes in inflammatory bowel disease at 10 Australian and New Zealand centers: Crohn's Colitis Cure data insights programMcnamara, J., Ghaly, S., Pipicella, J., Wilson, W., Goodfellow, T., Cheema, M., Lynch, K., Williams, A., Begun, J., Gearry, R., Kim, A., Haifer, C., Forbes, A., Lawrence, I., Schultz, M., Walker, G., Radford-Smith, G., Andrews, J. and Connor, S. (2023). Variation of outcomes in inflammatory bowel disease at 10 Australian and New Zealand centers: Crohn's Colitis Cure data insights program. HOBOKEN: WILEY. |
|
2023 Conference Publication The evolving role of technology in delivering consumer-centric care for inflammatory bowel disease: An Australasian experience with Crohn's Colitis Care's e-health consumer portalMcnamara, J., Pipicella, J., Ghaly, S., Gearry, R., Forbes, A., Begun, J., Wark, G., Lynch, K., Lawrence, I., Schultz, M., Walker, G., Radford-Smith, G., Brett, L., Verdon, C., Andrews, J. and Connor, S. (2023). The evolving role of technology in delivering consumer-centric care for inflammatory bowel disease: An Australasian experience with Crohn's Colitis Care's e-health consumer portal. HOBOKEN: WILEY. |
|
2023 Conference Publication Impact of disease duration on predicting response to vedolizumab in patients with ulcerative colitis from the Vedolizumab Immunomodulator Enforced Withdrawal Study (VIEWS)Choi, R. C-H, Pudipeddi, A., Lin, H., Paramsothy, S., Ghaly, S., Begun, J., Kariyawasam, V., Yau, Y., Fung, C. and Leong, R. (2023). Impact of disease duration on predicting response to vedolizumab in patients with ulcerative colitis from the Vedolizumab Immunomodulator Enforced Withdrawal Study (VIEWS). HOBOKEN: WILEY. |
|
2023 Journal Article Protocol for a single-arm feasibility study of photobiomodulation for fatigue, depression, and pain in inflammatory bowel diseaseEwais, Tatjana, Begun, Jakob and Laakso, E-Liisa (2023). Protocol for a single-arm feasibility study of photobiomodulation for fatigue, depression, and pain in inflammatory bowel disease. Biomedicines, 11 (8) 2179, 1-11. doi: 10.3390/biomedicines11082179 |
|
2023 Journal Article Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitisGilmore, Robert, Tan, Lian, Fernandes, Richard, An, Yoon-Kyo and Begun, Jakob (2023). Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitis. Journal of Crohn's and Colitis, 17 (12), 2033-2036. doi: 10.1093/ecco-jcc/jjad115 |
|
2023 Conference Publication Goblet cell specific anti-apoptotic role of interleukin-24 in spondyloarthritis-associated ileitisCameron, A., Giri, R., Begun, J., Wells, T., Bergot, A. S. and Thomas, R. (2023). Goblet cell specific anti-apoptotic role of interleukin-24 in spondyloarthritis-associated ileitis. EULAR 2023 European Congress of Rheumatology, Milan, Italy, 31 May-3 June 2023. London, United Kingdom: BMJ Group. doi: 10.1136/annrheumdis-2023-eular.1346 |
|
2023 Journal Article Upadacitinib induction and maintenance therapy for Crohn's diseaseLoftus, Edward V., Panés, Julian, Lacerda, Ana P., Peyrin-Biroulet, Laurent, D'Haens, Geert, Panaccione, Remo, Reinisch, Walter, Louis, Edouard, Chen, Minhu, Nakase, Hiroshi, Begun, Jakob, Boland, Brigid S., Phillips, Charles, Mohamed, Mohamed-Eslam F, Liu, Jianzhong, Geng, Ziqian, Feng, Tian, Dubcenco, Elena and Colombel, Jean-Frederic (2023). Upadacitinib induction and maintenance therapy for Crohn's disease. The New England journal of medicine, 388 (21), 1966-1980. doi: 10.1056/NEJMoa2212728 |
|
2023 Conference Publication WITHDRAWAL VERSUS CONTINUATION OF THIOPURINE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS (VIEWS): A MULTI-CENTRE RANDOMISED CONTROLLED TRIALPudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj C., Paramsothy, Ramesh, Ghaly, Dr Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark, De Cruz, Peter, Fung, Caroline, Chan, Pak Wo, Mourad, Fadi H., Redmond, Diane and Leong, Rupert (2023). WITHDRAWAL VERSUS CONTINUATION OF THIOPURINE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS (VIEWS): A MULTI-CENTRE RANDOMISED CONTROLLED TRIAL. Digestive Disease Week (DDW), Chicago Il, May 06-09, 2023. PHILADELPHIA: W B SAUNDERS CO-ELSEVIER INC. |
|
2023 Conference Publication Post-Ustekinumab induction IL-12, IL-13 and Ustekinumab levels are associated with clinical response in a multicentre prospective cohort study of Crohn's disease patients: results from the Aurora studyAn, Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Fernandes, Richard, Amiss, Anna, Pham, Hai, Wong, Kam Fai, Ooi, Soong-Yuan, Thin, Lena, Lightowler, Daniel, Connor, Susan J., Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nikola, Ghaly, Dr Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren S., Bryant, Robert V., Ding, Nik S., Leong, Rupert, Van Langenberg, Daniel R., Seltenreich, Hansjoerg, Subramaniam, Kavitha, Radford-Smith, Graham L. and Begun, Jakob (2023). Post-Ustekinumab induction IL-12, IL-13 and Ustekinumab levels are associated with clinical response in a multicentre prospective cohort study of Crohn's disease patients: results from the Aurora study. Digestive Disease Week DDW / AGA Conference 2023, Chicago, IL United States, 6-9 May 2023. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(23)03564-3 |
|
2023 Conference Publication Withdrawal Versus Continuation Of Thiopurine In Vedolizumab-treated Patients With Ulcerative Colitis (Views): A Multi-centre Randomised Controlled TrialPudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj C., Paramsothy, Ramesh, Ghaly, Dr Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark, De Cruz, Peter, Fung, Caroline, Chan, Pak Wo, Mourad, Fadi H., Redmond, Diane and Leong, Rupert (2023). Withdrawal Versus Continuation Of Thiopurine In Vedolizumab-treated Patients With Ulcerative Colitis (Views): A Multi-centre Randomised Controlled Trial. Digestive Disease Week (DDW) 2023, Chicago, IL United States, 6-9 May 2023. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(23)01488-9 |
|
2023 Conference Publication Reduction of bowel wall thickness and doppler signals as eary as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of acute severe ulcerative colitis: USUC study including genius cohortAn, Yoon-Kyo, Fernandes, Richard, Lindsay, Niamh, Khoo, Emi, Pham, Hai, Wong, Kam Fai, Thin, Lena, Goodsall, Thomas, Bryant, Robert V., Wright, Emily K., Smith, Rebecca, Friedman, Antony and Begun, Jakob (2023). Reduction of bowel wall thickness and doppler signals as eary as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of acute severe ulcerative colitis: USUC study including genius cohort. Digestive Disease Week (DDW), Chicago, IL United States, 6-9 May 2023. Philadelphia, PA United States: Elsevier. |
|
2023 Conference Publication Baseline cytokine levels and microbiome signatures are associted with clinical response following ustekinumab induction in a multi-centre prospective cohort study of crohn's disease patients: results from the aurora studyAn, Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Fernandes, Richard, Amiss, Anna, Pham, Hai, Giri, Rabina, Ooi, Soong-Yuan, Thin, Lena, Lightowler, Daniel, Connor, Susan J., Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nikola, Ghaly, Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren S., Bryant, Robert V., Ding, Nik S., Leong, Rupert, Van Langenberg, Daniel R., Seltenreich, Hansjoerg, Subramaniam, Kavitha, Radford-Smith, Graham L. and Begun, Jakob (2023). Baseline cytokine levels and microbiome signatures are associted with clinical response following ustekinumab induction in a multi-centre prospective cohort study of crohn's disease patients: results from the aurora study. Digestive Disease Week (DDW), Chicago, IL United States, 6-9 May 2023. Philadelphia, PA United States: Elsevier. doi: 10.1016/S0016-5085(23)02531-3 |
|
2023 Conference Publication Post-ustekinumab induction IL-12, IL-23, and ustekinumab levels are associated with clinical response in a multicentre prospective cohort study of Crohn's disease patients: results from the Aurora StudyAn, Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Fernandes, Richard, Amiss, Anna, Pham, Hai, Wong, Kam Fai, Ooi, Soong-Yuan, Thin, Lena, Lightowler, Daniel, Connor, Susan J., Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nikola, Ghaly, Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren S., Bryant, Robert V., Ding, Nik S., Leong, Rupert, Van Langenberg, Daniel R., Seltenreich, Hansjoerg, Subramaniam, Kavitha, Radford-Smith, Graham L. and Begun, Jakob (2023). Post-ustekinumab induction IL-12, IL-23, and ustekinumab levels are associated with clinical response in a multicentre prospective cohort study of Crohn's disease patients: results from the Aurora Study. Digestive Disease Week (DDW), Chicago, IL United States, 6-9 May 2023. Philadelphia, PA United States: Elsevier. |
